Skip to main content
Erschienen in: Journal of Bone and Mineral Metabolism 5/2020

13.05.2020 | Original Article

Aromatase inhibitors attenuate the effect of alendronate in women with breast cancer

verfasst von: Sung Hye Kong, Jung Hee Kim, Sang Wan Kim, Chan Soo Shin

Erschienen in: Journal of Bone and Mineral Metabolism | Ausgabe 5/2020

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Aromatase inhibitors are known to accelerate bone loss in patients with breast cancer. However, how much AIs affect the efficacy of antiresorptive agents has not been studied. The study aimed to compare the effect of alendronate on bone mineral density (BMD) between patients with and without AI treatment.

Materials and methods

In this retrospective study, 90 postmenopausal women with early breast cancer who were being treated with both AI and alendronate 70 mg weekly (ALN + AI), and 90 age- and body mass index (BMI)-matched patients who were only taking alendronate (ALN-only) were analyzed. BMD and bone turnover markers (BTMs) were assessed at the baseline and 12 months.

Results

The mean age was 63 years. At baseline, the ALN-only group had lower lumbar spine (LS), femur neck (FN), and total hip (TH) BMD than ALN + AI group. After 1-year of alendronate treatment, the LS and FN BMD were improved more in the ALN-only group than those in the ALN + AI group after adjustments for age, BMI, baseline BMD, diabetes, hypertension, renal function, and previous fracture history [LS BMD: 6.2% (3.1%; 9.2%) in ALN-only, 3.5% (−0.5%; 6.5%) in ALN + AI, p = 0.001; FN BMD: 2.5% (0.3%; 5.7%) in ALN-only, 0.9% (− 1.8%; 3.6%) in ALD + AI, p = 0.032]. BTMs were significantly decreased in both groups, but the changes between groups were similar.

Conclusion

The effect of alendronate on the LS and FN BMD was attenuated in postmenopausal women who were taking AI compared to those who were not on AI.
Literatur
1.
Zurück zum Zitat Burstein HJ, Temin S, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Rowden D, Solky AJ (2014) Adjuvant endocrine therapy for women with hormone receptor–positive breast cancer: American Society of clinical oncology clinical practice guideline focused update. J Clin Oncol 32:2255CrossRef Burstein HJ, Temin S, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Rowden D, Solky AJ (2014) Adjuvant endocrine therapy for women with hormone receptor–positive breast cancer: American Society of clinical oncology clinical practice guideline focused update. J Clin Oncol 32:2255CrossRef
2.
Zurück zum Zitat Hadji P (2009) Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis. Critic Rev Oncol/Hematol 69:73–82CrossRef Hadji P (2009) Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis. Critic Rev Oncol/Hematol 69:73–82CrossRef
4.
Zurück zum Zitat Hines SL, Sloan JA, Atherton PJ, Perez EA, Dakhil SR, Johnson DB, Reddy PS, Dalton RJ, Mattar BI, Loprinzi CL (2010) Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy. Breast (Edinburgh, Scotland) 19:92–96. https://doi.org/10.1016/j.breast.2009.12.001CrossRef Hines SL, Sloan JA, Atherton PJ, Perez EA, Dakhil SR, Johnson DB, Reddy PS, Dalton RJ, Mattar BI, Loprinzi CL (2010) Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy. Breast (Edinburgh, Scotland) 19:92–96. https://​doi.​org/​10.​1016/​j.​breast.​2009.​12.​001CrossRef
5.
Zurück zum Zitat Safra T, Bernstein-Molho R, Greenberg J, Pelles-Avraham S, Stephansky I, Sarid D, Inbar MJ, Stemmer SM, Geffen DB (2011) The protective effect of zoledronic acid on bone loss in postmenopausal women with early breast cancer treated with sequential tamoxifen and letrozole: a prospective, randomized, phase II trial. Oncol 81:298–305. https://doi.org/10.1159/000334456CrossRef Safra T, Bernstein-Molho R, Greenberg J, Pelles-Avraham S, Stephansky I, Sarid D, Inbar MJ, Stemmer SM, Geffen DB (2011) The protective effect of zoledronic acid on bone loss in postmenopausal women with early breast cancer treated with sequential tamoxifen and letrozole: a prospective, randomized, phase II trial. Oncol 81:298–305. https://​doi.​org/​10.​1159/​000334456CrossRef
9.
11.
Zurück zum Zitat Rhee Y, Song K, Park S, Park HS, Lim SK, Park BW (2013) Efficacy of a combined alendronate and calcitriol agent (Maxmarvil(R)) in Korean postmenopausal women with early breast cancer receiving aromatase inhibitor: a double-blind, randomized, placebo-controlled study. Endocrine J 60:167–172CrossRef Rhee Y, Song K, Park S, Park HS, Lim SK, Park BW (2013) Efficacy of a combined alendronate and calcitriol agent (Maxmarvil(R)) in Korean postmenopausal women with early breast cancer receiving aromatase inhibitor: a double-blind, randomized, placebo-controlled study. Endocrine J 60:167–172CrossRef
13.
Zurück zum Zitat Pineda‐Moncusí M, Garcia‐Giralt N, Diez‐Perez A, Servitja S, Tusquets I, Prieto‐Alhambra D, Nogués X (2019) Increased fracture risk in women treated with aromatase inhibitors versus tamoxifen: beneficial effect of bisphosphonates. J Bone Miner Res Pineda‐Moncusí M, Garcia‐Giralt N, Diez‐Perez A, Servitja S, Tusquets I, Prieto‐Alhambra D, Nogués X (2019) Increased fracture risk in women treated with aromatase inhibitors versus tamoxifen: beneficial effect of bisphosphonates. J Bone Miner Res
14.
Zurück zum Zitat Galvano A, Scaturro D, Badalamenti G, Incorvaia L, Rizzo S, Castellana L, Cusenza S, Cutaia S, Santini D, Guadagni F (2019) Is there a role for denosumab and bone health for prostate and breast cancer patients undergoing endocrine therapy? A systematic review and a meta-analysis of randomized trials. J Bone Oncol 100:252 Galvano A, Scaturro D, Badalamenti G, Incorvaia L, Rizzo S, Castellana L, Cusenza S, Cutaia S, Santini D, Guadagni F (2019) Is there a role for denosumab and bone health for prostate and breast cancer patients undergoing endocrine therapy? A systematic review and a meta-analysis of randomized trials. J Bone Oncol 100:252
16.
Zurück zum Zitat Janni W, Hepp P (2010) Adjuvant aromatase inhibitor therapy: outcomes and safety. Can Treat Rev 36:249–261CrossRef Janni W, Hepp P (2010) Adjuvant aromatase inhibitor therapy: outcomes and safety. Can Treat Rev 36:249–261CrossRef
19.
21.
Zurück zum Zitat Hong A, Kim JH, Lee K-H, Kim T-Y, Im S-A, Moon H, Han W, Noh D, Kim S, Shin C (2017) Long-term effect of aromatase inhibitors on bone microarchitecture and macroarchitecture in non-osteoporotic postmenopausal women with breast cancer. Osteoporos Int 28:1413–1422CrossRef Hong A, Kim JH, Lee K-H, Kim T-Y, Im S-A, Moon H, Han W, Noh D, Kim S, Shin C (2017) Long-term effect of aromatase inhibitors on bone microarchitecture and macroarchitecture in non-osteoporotic postmenopausal women with breast cancer. Osteoporos Int 28:1413–1422CrossRef
22.
Zurück zum Zitat Khosla S, Melton LJ III, Riggs BL (2011) The unitary model for estrogen deficiency and the pathogenesis of osteoporosis: is a revision needed? J Bone Miner Res 26:441–451CrossRef Khosla S, Melton LJ III, Riggs BL (2011) The unitary model for estrogen deficiency and the pathogenesis of osteoporosis: is a revision needed? J Bone Miner Res 26:441–451CrossRef
23.
Zurück zum Zitat Mirza FS, Padhi ID, Raisz LG, Lorenzo JA (2010) Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J Clin Endocrinol Metab 95:1991–1997CrossRef Mirza FS, Padhi ID, Raisz LG, Lorenzo JA (2010) Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J Clin Endocrinol Metab 95:1991–1997CrossRef
24.
Zurück zum Zitat Mödder UI, Clowes JA, Hoey K, Peterson JM, McCready L, Oursler MJ, Riggs BL, Khosla S (2011) Regulation of circulating sclerostin levels by sex steroids in women and in men. J Bone Miner Res 26:27–34CrossRef Mödder UI, Clowes JA, Hoey K, Peterson JM, McCready L, Oursler MJ, Riggs BL, Khosla S (2011) Regulation of circulating sclerostin levels by sex steroids in women and in men. J Bone Miner Res 26:27–34CrossRef
25.
Zurück zum Zitat Morales-Santana S, Díez-Pérez A, Olmos JM, Nogués X, Sosa M, Díaz-Curiel M, Pérez-Castrillón JL, Pérez-Cano R, Torrijos A, Jodar E (2015) Circulating sclerostin and estradiol levels are associated with inadequate response to bisphosphonates in postmenopausal women with osteoporosis. Maturitas 82:402–410CrossRef Morales-Santana S, Díez-Pérez A, Olmos JM, Nogués X, Sosa M, Díaz-Curiel M, Pérez-Castrillón JL, Pérez-Cano R, Torrijos A, Jodar E (2015) Circulating sclerostin and estradiol levels are associated with inadequate response to bisphosphonates in postmenopausal women with osteoporosis. Maturitas 82:402–410CrossRef
28.
Zurück zum Zitat Hadji P, Gottschalk M, Ziller V, Kalder M, Jackisch C, Wagner U (2007) Bone mass and the risk of breast cancer: the influence of cumulative exposure to oestrogen and reproductive correlates. Results of the Marburg breast cancer and osteoporosis trial (MABOT). Maturitas 56:312–321CrossRef Hadji P, Gottschalk M, Ziller V, Kalder M, Jackisch C, Wagner U (2007) Bone mass and the risk of breast cancer: the influence of cumulative exposure to oestrogen and reproductive correlates. Results of the Marburg breast cancer and osteoporosis trial (MABOT). Maturitas 56:312–321CrossRef
29.
Zurück zum Zitat Kim W, Chung Y, Kim SH, Park S, Bae JH, Kim G, Lee SJ, Kim JE, Park B-W, Lim S-K (2015) Increased sclerostin levels after further ablation of remnant estrogen by aromatase inhibitors. Endocrinol Metab 30:58–64CrossRef Kim W, Chung Y, Kim SH, Park S, Bae JH, Kim G, Lee SJ, Kim JE, Park B-W, Lim S-K (2015) Increased sclerostin levels after further ablation of remnant estrogen by aromatase inhibitors. Endocrinol Metab 30:58–64CrossRef
Metadaten
Titel
Aromatase inhibitors attenuate the effect of alendronate in women with breast cancer
verfasst von
Sung Hye Kong
Jung Hee Kim
Sang Wan Kim
Chan Soo Shin
Publikationsdatum
13.05.2020
Verlag
Springer Singapore
Erschienen in
Journal of Bone and Mineral Metabolism / Ausgabe 5/2020
Print ISSN: 0914-8779
Elektronische ISSN: 1435-5604
DOI
https://doi.org/10.1007/s00774-020-01111-3

Weitere Artikel der Ausgabe 5/2020

Journal of Bone and Mineral Metabolism 5/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Deeskalation in der Systemtherapie: Das Ziel muss bekannt sein

21.06.2024 Senologiekongress 2024 Kongressbericht

Anhand des Brustkrebssubtyps und des Risikos kann die Eskalationsstufe der Behandlung beim frühen Mammakarzinom festgelegt werden. Prof. Christian Jackisch, Essen, gab beim 43. Jahreskongress der Deutschen Gesellschaft für Senologie einen Einblick in bestehende Konzepte.

Wie wird Brustkrebs in zehn Jahren behandelt?

21.06.2024 Senologiekongress 2024 Kongressbericht

Beim 43. Jahreskongress der Deutschen Gesellschaft für Senologie haben vier Behandelnde verschiedener Fachrichtungen einen Blick in die Zukunft der Brustkrebstherapie gewagt. Wie könnte sie im Jahr 2034 aussehen?

Cannabis wirkt nicht antientzündlich

Cannabinoide Nachrichten

Die Wirksamkeit von Cannabisprodukten ist in einigen medizinischen Indikationen gesichert. Aber längst nicht alle Effekte, die Cannabis zugesprochen werden, lassen sich in Studien nachvollziehen. In der randomisierten, placebokontrollierten Studie MedCan-1 wurde der antiinflammatorische Effekt von Cannabidiol genauer unter die Lupe genommen.

So beeinflussen Herzinfarkte auf lange Sicht die Sterblichkeit

20.06.2024 ST-Hebungsinfarkt Nachrichten

Wie hoch ist bei Patienten, die nach einem ST-Hebungs-Myokardinfarkt die initiale Hochrisikophase überleben, auf lange Sicht das Sterberisiko? Eine Studie aus Dänemark liefert dazu nun aufschlussreiche Daten.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.